Immuneering to present data from Phase 2a trial of IMM-1-104 in early January

Immuneering (IMRX) will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104. Specifically, the company plans to present: Additional data from IMM-1-104 in combination with mGnP in first-line pancreatic cancer. Initial data from IMM-1-104 in combination with mFFX in first-line pancreatic cancer. Initial data from IMM-1-104 monotherapy in second-line pancreatic cancer.In addition, the company will provide initial PK, PD and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415. Details of how to access the Investor Event will be provided in due course.